Related Experiment Video
Updated: Jan 8, 2026

Comparing the Affinity of GTPase-binding Proteins using Competition Assays
Published on: October 8, 2015
Recent breakthroughs in understanding the allosteric features of Ras GTPases and their effector and regulatory
Nisha Bhattarai1, Matthias Buck2
1Department of Physiology & Biophysics, Case Western Reserve University, Cleveland, OH 44106, USA.
Abstract:
Ras guaosine triphosphate hydrolase (GTPase) are central to key cell signaling pathways and, when mutated, drive many cancers. Thought to be undruggable, dramatic progress has been made in the last decade in the design and screening of drugs, in large part thanks to an emerging detailed understanding of Ras conformational changes, excited/sparsely populated states, and allosteric interactions with ligands and protein-binding partners. This perspective reviews this recent progress and how it has been enabled by deep mutational scanning, solution nuclear magnetic resonance (NMR) spectroscopic studies, as well as computational modeling and simulations. We critically discuss these developments over the last 5 years, also for the GTPase-activating proteins (GAP) NF1 and plexin, effector proteins, plexin and Raf, and make suggestions on the gaps in our understanding that still exist.
Insights
Targeting Ras GTPase proteins, mutated in many cancers, is advancing rapidly. Recent progress in drug discovery for these previously undruggable targets is reviewed, highlighting new insights into Ras conformational dynamics and interactions.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Ras guanosine triphosphate hydrolases (GTPases) are crucial in cell signaling.
- Mutations in Ras GTPases are implicated in driving numerous cancers.
- Ras proteins were historically considered undruggable targets for cancer therapy.
Purpose of the Study:
- To review recent advancements in Ras-targeted drug discovery.
- To highlight the role of understanding Ras conformational changes and interactions in this progress.
- To discuss developments concerning GTPase-activating proteins (GAP) and effector proteins.
Main Methods:
- Deep mutational scanning
- Solution nuclear magnetic resonance (NMR) spectroscopy
- Computational modeling and simulations
Main Results:
- Significant progress has been made in designing and screening Ras-targeting drugs.
- Detailed understanding of Ras conformational dynamics, sparse populations, and allosteric interactions is key.
- Recent developments have also impacted studies on NF1, plexin, and Raf proteins.
Conclusions:
- The past five years have seen dramatic progress in targeting Ras GTPases for cancer therapy.
- Advanced techniques have elucidated critical aspects of Ras protein behavior.
- Further research is needed to address existing gaps in understanding for comprehensive therapeutic strategies.
More Related Videos
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
GTPases and their Regulation
Large G-proteins,...
GTPases and their Regulation
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
The Ras Gene
Ras is a...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...

